MAPT and Alzheimer disease: Seeking to identify a cerebrovascular “signature” of Aβ pathology in AD, we investigated the degree to which CVD neuroimaging biomarkers—including CMBs, lacunar infarction, and WMHs—correlate with Aβ‐PET positivity, a core biomarker of AD under the Amyloid/Tau/Neurodegeneration framework.2